Platinum
Platinum is a chemical element whose coordination complexes have an established role in anticancer therapy.
Platinum is a chemical element whose coordination complexes have an established role in anticancer therapy. In oncology, “platinum” commonly refers to platinum-based chemotherapy, including cisplatin, carboplatin, and oxaliplatin. These agents form platinum–DNA adducts that disrupt DNA replication and transcription, producing DNA damage and, in susceptible cancer cells, apoptotic cell death. Platinum therapy is used across several malignancies, including ovarian cancer, lung cancer, breast cancer, and stomach cancer, and may be administered with other chemotherapy, radiation therapy, or immunotherapy.
The therapeutic value of platinum compounds is limited by toxicity, acquired or intrinsic resistance, and incomplete selectivity for cancer cells. Current research is therefore extending platinum therapy through redesigned Pt(II) complexes, drug-delivery systems, catalytic nanoparticles, and combination treatments intended to enhance cytotoxicity or overcome resistance. The supplied literature is concentrated on platinum therapy resistance, targeted cancer treatment strategies, and nanomedicine for cancer therapy, with particular attention to DNA-damage responses, RNA metabolism, tumor microenvironmental effects, and treatment selection in genetically defined cancers.
- Green synthesis of CuO nanoparticles using mangrove leaves for targeted delivery of platinum (II) therapeutics. PMID 42711436
- An Inhalable Hybrid Nitric Oxide Nanogenerator for Lung Adenocarcinoma Treatment via Bioorthogonal-Activated Gas-Immunotherapy. PMID 42714559
- Chemical Stabilization and Transformation of Schiff Base Scaffold: A Path toward Superior Platinum-Based Anti-Cancer Stem Cell Drugs. PMID 42720472
Where the papers sit
10 papers study platinum directly. The themes below are drawn from those 10. 1 paradigm shift and 1 new direction follow.
-
Platinum Therapy Resistance : Resistance biology is being linked to RNA metabolism, enhancer-associated MSH6 loss, transcriptional condensates and immune features in ovarian cancer. CDK12/13 inhibition, platinum nanozymes and mutational surveillance offer parallel routes to improve or monitor therapy. 4 papers · 40%
-
Targeted Cancer Treatment Strategies : Platinum chemotherapy is being combined with immunotherapy, radioimmunotherapy or gene editing, while stabilized scaffolds target cancer stem cells. Treatment selection and survival are also being assessed by BRCA1/2 and HER2 status in breast and lung cancer. 4 papers · 40%
-
Nanomedicine for Cancer Therapy : Targeted nanoparticles are pairing platinum drugs or nitric oxide with immune activation and controlled delivery. Green CuO synthesis and inhalable bioorthogonal gas generation point toward multifunctional treatments for lung adenocarcinoma. 2 papers · 20%
Platinum resistance is a reversible systems state rather than an irreversible endpoint of platinum treatment
The epithelial ovarian cancer study of pharmacological CDK12/13 inhibition found that disrupting transcriptional elongation and RNA processing enhanced platinum cytotoxicity, delayed resistant recurrence, and even made tumors that acquired CDK12-inhibitor resistance more platinum-sensitive 42686681Sep. The lung adenocarcinoma study of an inhalable nitric-oxide/cisplatin nanogenerator likewise used tumor-microenvironment reprogramming to restore or potentiate platinum-mediated damage while limiting off-target toxicity 42714559Sep. Together, these independently studied models indicate that platinum resistance can be defeated by targeting dependencies outside the platinum molecule itself—RNA metabolism in ovarian cancer and the tumor microenvironment in lung cancer—shifting the therapeutic problem from replacing platinum to making resistant tumors responsive to it again.
Platinum is implicated as a long-latency cause of genomic change in subsequent neoplasms
The childhood-cancer-survivor study of therapy-related breast, meningioma, and thyroid subsequent neoplasms found that prior platinum treatment correlated with NF2 splice-site variants in meningiomas arising decades later 42001506Apr. This assigns platinum a role not represented elsewhere in the set—as a treatment-associated exposure linked to the genomic evolution of a later, independent cancer—rather than as an active anticancer drug, resistance modulator, delivery component, catalyst, or radiation sensitizer.
Recent Findings on platinum
A Journal of Medicinal Chemistry study described two Pt(II) complexes based on a Schiff base ligand and its reduced imine derivative. The compounds were designed to address limitations of existing platinum-based anticancer stem cell drugs, representing a strategy of chemical scaffold stabilization and transformation rather than use of a conventional platinum chemotherapy backbone 42720472Sep.
Platinum was incorporated into an inhalable hybrid nitric oxide nanogenerator for lung adenocarcinoma treatment. In this design, a Pt-based catalyst and a caged nitric oxide donor were integrated into a single prodrug and encapsulated within a disulfide-cross-linked organosilica shell. The system was designed to enable redox-triggered, self-catalytic nitric oxide release while reducing off-target injury to normal tissues, linking platinum chemistry with gas therapy, reactive oxygen or redox biology, and immune activation 42714559Sep.
In young BRCA1/2 carriers with HER2-negative early breast cancer, a study evaluated the association between platinum use and clinical outcomes in triple-negative breast cancer (TNBC). The work addressed whether platinum-containing chemotherapy has particular relevance for treatment selection in genetically defined breast cancer, with survival as an outcome of interest 42580099Aug.
Platinum delivery was investigated using copper(II) oxide nanoparticles produced through a green synthesis based on mangrove leaves. The CuO nanoparticles were evaluated as nanocarriers for the clinically relevant Pt(II) chemotherapeutics cisplatin and oxaliplatin, illustrating an approach intended to combine platinum chemotherapy with nanoparticle-mediated delivery 42711436Sep.
A study of epithelial ovarian cancer examined whether inhibition of cyclin-dependent kinases CDK12 and CDK13 could overcome platinum resistance. Pharmacological CDK12/13 inhibition enhanced platinum-induced cytotoxicity across a large set of platinum-sensitive and platinum-resistant ovarian cancer models, supporting a combination strategy that links platinum treatment to impaired RNA metabolism 42686681Sep.
Platinum exposure was also examined in the context of therapy-related mutational signatures among survivors of childhood cancer. In meningioma, prior platinum therapy correlated with NF2 splice-site variants, providing an example of how platinum treatment may be associated with genomic alterations in subsequent neoplasms 42001506Apr.
In patients with EGFR-mutated advanced non-small-cell lung cancer (NSCLC) who developed neuroendocrine transformation after first-line osimertinib, the ORCHARD study investigated durvalumab combined with etoposide-platinum. Patients received durvalumab intravenously every three weeks together with etoposide-platinum every three weeks for up to four cycles, placing platinum chemotherapy within an immunotherapy-containing treatment regimen 42361644Jun.
Platinum resistance in ovarian cancer was further investigated through multi-omics profiling. The study linked enhancer-associated downregulation of MSH6 with platinum resistance, prognosis, and immune features, highlighting a possible relationship between DNA-repair biology, epigenetic regulation, and the tumor microenvironment 41911956Mar.
A high-entropy alloy containing platinum, gold, bismuth, silver, and palladium was integrated with gene editing for cocktail-sensitized radioimmunotherapy of lung metastases. This work placed platinum within a multifunctional alloy platform rather than using it as a conventional soluble chemotherapy agent, combining materials engineering with gene-based and radiation-associated treatment concepts 41914367Mar.
Platinum nanozymes were engineered at the atomic and particle scales for catalytic therapy. Porous silica nanoflowers bearing Pt-based nanozymes with differing particle sizes but equivalent metal loadings were designed and synthesized for antibacterial activity and cascade catalytic tumor therapy, extending platinum research into catalytic generation or modulation of biologically active chemical species 42328814Jun.
Together, these publications extend all three major themes represented in the supplied literature. Resistance-focused work connects platinum response to CDK12/13-dependent RNA metabolism, MSH6-associated molecular features, and therapy-related mutational patterns. Treatment-strategy studies combine platinum with durvalumab-based immunotherapy, gene editing, nitric oxide biology, or molecularly selected chemotherapy for BRCA1/2-associated TNBC and transformed EGFR-mutated NSCLC. Nanomedicine studies pursue controlled delivery of cisplatin and oxaliplatin, inhalable platinum-enabled prodrugs, and Pt-based nanozymes, with the shared goal of improving tumor selectivity while preserving or increasing cytotoxicity.
Written from 10 PubMed abstracts, each one cited by PMID above. Published: 2026-09-11. Drafted by language models from published abstracts; not medical advice.